The internal pool of GPIIb/IIIa, which is expressed upon platelet activation, may be inaccessible to inhibition by GPIIb/IIIa an-tagonists. To determine the occupancy of the internal and external pools of GPIIb/IIIa and platelet function following an abciximab bolus and infusion, 15 patients undergoing elective percutaneous transluminal coronary angioplasty were adminis-tered abciximab as a bolus and 36-h infusion. GPIIb/IIIa recep-tor number and occupancy in resting and TRAP-6 (20 mM)-activated samples (to expose the internal pool of GPIIb/IIIa) was quantified using a monoclonal antibody-based assay. Antibody binding was quantified by flow cytometry and platelet inhibition by light transmittance aggregation and by the rapid platelet functi...
Objectives.This study sought to describe in detail the pharmacokinetics and pharmacodynamics of chim...
Background—Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclonal antibody frag...
Platelet-derived microparticles that are produced during platelet activation bind to traumatized end...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules...
Abciximab is a new antiplatelet therapeutic in ischemic cardiovascular disease. The drug, chimeric F...
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagon...
Background—Tests developed to monitor glycoprotein (GP) IIb/IIIa blockade do not properly reflect pl...
Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacolog...
In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividu...
The glycoprotein (GP) IIb/IIIa receptor is critical to the process of platelet aggregation and throm...
The pharmacodynamics of intravenous bolus injections of 0.05, 0.10, 0.15, and 0.20 mg/kg of F(ab&apo...
Platelet deposition and aggregation are the major determinants of acute thrombosis in coronary stent...
BACKGROUND: The best method for measuring the degree of platelet inhibition with glycoprotein (GP) I...
Coronary artery disease and acute myocardial infarction still represent the leading cause of mortali...
Objectives.This study sought to describe in detail the pharmacokinetics and pharmacodynamics of chim...
Background—Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclonal antibody frag...
Platelet-derived microparticles that are produced during platelet activation bind to traumatized end...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules...
Abciximab is a new antiplatelet therapeutic in ischemic cardiovascular disease. The drug, chimeric F...
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagon...
Background—Tests developed to monitor glycoprotein (GP) IIb/IIIa blockade do not properly reflect pl...
Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacolog...
In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividu...
The glycoprotein (GP) IIb/IIIa receptor is critical to the process of platelet aggregation and throm...
The pharmacodynamics of intravenous bolus injections of 0.05, 0.10, 0.15, and 0.20 mg/kg of F(ab&apo...
Platelet deposition and aggregation are the major determinants of acute thrombosis in coronary stent...
BACKGROUND: The best method for measuring the degree of platelet inhibition with glycoprotein (GP) I...
Coronary artery disease and acute myocardial infarction still represent the leading cause of mortali...
Objectives.This study sought to describe in detail the pharmacokinetics and pharmacodynamics of chim...
Background—Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclonal antibody frag...
Platelet-derived microparticles that are produced during platelet activation bind to traumatized end...